🧬 PD-L1 Cancer Research

PD-L1 is an immune checkpoint protein that has become one of the most important biomarkers in modern cancer research. This protein sits on the surface of cancer cells and acts like a "brake" on the immune system, helping tumors evade detection and attack by the body's natural defenses. By understanding PD-L1 levels, researchers and oncologists can better predict which patients may respond to immunotherapy treatments, a category of drugs designed to release these brakes and allow the immune system to fight cancer more effectively.

Over the past decade, PD-L1 testing has transformed from a research curiosity into a standard diagnostic tool in cancer care. Measuring PD-L1 expression in tumors helps oncologists determine which patients might benefit most from checkpoint inhibitor drugs and which individuals may need alternative or combination treatment strategies. This biomarker-driven approach represents a shift toward precision medicine, where treatment decisions are based on individual tumor characteristics rather than a one-size-fits-all approach. Current research continues to explore how PD-L1 levels relate to treatment outcomes across different cancer types, how to best measure this biomarker, and whether PD-L1 status can help predict response to newer immunotherapy combinations.

On this page, you'll find summaries of the latest peer-reviewed studies examining PD-L1 as a cancer biomarker and diagnostic tool. These articles represent cutting-edge research from institutions worldwide focused on improving how we identify patients most likely to benefit from immunotherapy and advancing the field of personalized cancer treatment.